SC 13G: Aclaris Therapeutics, Inc.
Ticker: ACRS · Form: SC 13G · Filed: Nov 25, 2024 · CIK: 1557746
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by Aclaris Therapeutics, Inc..
Risk Assessment
Risk Level: low
Filing Stats: 995 words · 4 min read · ~3 pages · Grade level 7.2 · Accepted 2024-11-25 11:02:19
Key Financial Figures
- $0.00001 — , INC. (Name of Issuer) COMMON STOCK, $0.00001 PAR VALUE (Title of Class of Securitie
Filing Documents
- sc13g.htm (SC 13G) — 62KB
- 0000929638-24-004037.txt ( ) — 64KB
Ownership
Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 11,281,985 (b) Percent of class: 9.5% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 11,281,985 (ii) Shared power to vote or to direct the vote: 0 CUSIP No. 00461U105 13G Page 4 of 5 Pages (iii) Sole power to dispose or to direct the disposition of: 11,281,985 (iv) Shared power to dispose or to direct the disposition of: 0
Ownership of Five Percent or Less of a Class
Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:
Ownership of More than Five Percent on Behalf of Another Person
Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not applicable.
Identification and Classification of Members of the Group
Item 8. Identification and Classification of Members of the Group. Not applicable.
Notice of Dissolution of Group
Item 9. Notice of Dissolution of Group. Not applicable.
Certification
Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. 00461U105 13G Page 5 of 5 Pages After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 25, 2024 Date Biosion, Inc. By: /s/ MINGJIU CHEN Name: MINGJIU CHEN Title: CEO